^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FUS-DDIT3 translocation

    i
    Other names: FUS, FUS RNA Binding Protein, TLS, Heterogeneous Nuclear Ribonucleoprotein P2, Translocated In Liposarcoma Protein, 75 KDa DNA-Pairing Protein, RNA-Binding Protein FUS, Fused In Sarcoma, Oncogene FUS, Oncogene TLS, HNRNPP2, FUS1, Fusion (Involved In T(12;16) In Malignant Liposarcoma), Fusion, Derived From T(12;16) Malignant Liposarcoma, Fusion Gene In Myxoid Liposarcoma, Amyotrophic Lateral Sclerosis 6, Translocated In Liposarcoma, Fus-Like Protein, HnRNP-P2, POMP75, POMp75, ALS6, ETM4, DDIT3, D
    Entrez ID:
    2521; 1649
    Related biomarkers:
    Fusion
    over2years
    IMMUNE INFILTRATE AND CELL CYCLE / DIFFERENTIATION PROGRAMS ARE INVERSELY CORRELATED IN MYXOID LIPOSARCOMA AND IDENTIFY HIGHER RISK PATIENTS (CTOS 2021)
    These findings suggested that in MLS dysregulation of genes promoting cell cycle progression and dedifferentiation of tumor cells were associated with shorter DFS and is likely the driver regulating anti-tumor immune response. Although the association between MLS genetic profile (Genetic score) and immunity (Immune score), and involvement of program dictated by the oncogenic translocation remain to be investigated, they suggest a therapeutic synergism in co-targeting cell cycle progression and immunity in MLS.
    Clinical • IO biomarker
    |
    FUS (FUS RNA Binding Protein) • DDIT3 (DNA-damage-inducible transcript 3)
    |
    FUS-DDIT3 translocation